| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FBXO38 |
| Uniprot No | Q6PIJ6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-426aa |
| 氨基酸序列 | MEEGDAESSVCPRCCCHRPQESQRRTSRCSDEERPSTSRACVVNGPDGTRSAFSFRTLPQGGSSGPAHDERTNGSGSGATGEDRRGSSQPESCDVQSNEDYPRRPLTRARSRLSHVLLVSESEVAKTKPRHAMKRKRTADKSTSTSDPVIEDDHVQVLVLKSKNLVGVTMTNCGITDLVLKDCPKMMFIHATRCRVLKHLKVENAPIVNRFDYAQCKKLNMDQVLDQILRMPPERNRIIYLRPMQQVDTLTLEQKLFSGPYPYHICIIHEFSNPPNVRNKVRIRSWMDTIANINQELIKYEFFPEATRSEEDLKKYPKYPWGREIYTLEGVVDGAPYSMISDFPWLRSLRAAEPNSFARYDFEDDEESTIYAPRRKGQLSADICMETIGEEISEMRQMKKGVFQRVVAIFIHYCDVNGEPVEDDYI |
| 分子量 | 75.1 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FBXO38蛋白的3篇文献的示例性参考(基于已知研究领域虚拟构造，实际文献需在学术库中检索确认)：
1. **文献名称**：*"FBXO38 mediates PD-1 ubiquitination and regulates anti-tumor immunity"*
**作者**：Meng, Q. et al.
**摘要**：研究揭示FBXO38作为E3泛素连接酶组分，通过泛素化修饰T细胞表面的PD-1蛋白，促进其降解，从而增强T细胞抗肿瘤活性。文中利用重组人FBXO38蛋白验证其与PD-1的相互作用及功能。
2. **文献名称**：*"Structural insights into FBXO38's substrate recognition mechanism"*
**作者**：Zhang, L. & Wang, H.
**摘要**：通过解析重组人FBXO38蛋白的晶体结构，阐明其F-box结构域和底物结合区的构象特征，为设计针对FBXO38相关疾病的分子靶向策略提供依据。
3. **文献名称**：*"FBXO38 modulates neuronal apoptosis via ubiquitination of MAPK signaling components"*
**作者**：Chen, R. et al.
**摘要**：研究报道FBXO38通过泛素化通路调控神经元凋亡，重组FBXO38蛋白实验证实其与MAPK通路蛋白的结合能力，提示其在神经退行性疾病中的潜在作用。
4. **文献名称**：*"Functional characterization of recombinant human FBXO38 in vitro"*
**作者**：Kim, S. & Park, J.
**摘要**：优化重组人FBXO38蛋白的原核表达与纯化流程，并验证其在体外泛素化反应中的酶活性，为后续机制研究提供可靠工具。
---
建议通过PubMed或Google Scholar检索具体文献(关键词："FBXO38 recombinant"、"FBXO38 ubiquitination")，以获取真实发表的研究成果。
Recombinant human FBXO38 protein is a key component in the ubiquitin-proteasome system, belonging to the F-box protein family characterized by a conserved F-box domain. FBXO38 acts as a substrate-recognition subunit within the SCF (SKP1-Cullin-F-box) E3 ubiquitin ligase complex, which mediates targeted protein degradation by tagging specific substrates with ubiquitin molecules. Structurally, FBXO38 contains an F-box domain for binding SKP1 and a C-terminal leucine-rich repeat (LRR) domain responsible for substrate interaction. Research highlights its role in regulating immune responses and cellular homeostasis. Notably, FBXO38 interacts with USP4 (a deubiquitinating enzyme) and facilitates its degradation, thereby modulating T-cell activation and immune tolerance. Dysregulation of FBXO38 has been linked to autoimmune diseases, cancer, and neurological disorders. For instance, it targets the oncoprotein c-Myc for degradation, suggesting tumor-suppressive potential. Recombinant FBXO38 is typically produced via bacterial or mammalian expression systems, enabling biochemical studies, structural analysis, and drug discovery. Its study provides insights into ubiquitination mechanisms, immune regulation, and therapeutic targeting of diseases associated with protein stability. Current challenges include clarifying its full range of substrates and tissue-specific functions.
×
